SCHEMBL2198973

SCHEMBL2198973

Cc1cc(F)ccc1Nc1ccc(C(=O)c2cc(C(=O)NCc3ccccn3)ccc2C)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 3/20 0.61
MAPK12 P53778 3/20 0.61
MAPK11 Q15759 3/20 0.61
MAPK14 Q16539 3/20 0.61
KDM4E B2RXH2 2/20 0.56
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
PRNP P04156 1/20 0.50
RAB9A P51151 3/20 0.49
HPGD P15428 2/20 0.49
ALDH1A1 P00352 2/20 0.47
NAMPT P43490 1/20 0.47
GRM4 Q14833 1/20 0.44
NPC1 O15118 2/20 0.44
P2RX7 Q99572 1/20 0.44
DGAT2 Q96PD7 1/20 0.43
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199931 0.86 MAPK14 (0.59) MAPK13MAPK12MAPK11MAPK14CYP3A4
SCHEMBL2198760 0.85 MAPK13 (0.58) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL2198608 0.83 MAPK14 (0.64) MAPK13MAPK12MAPK11MAPK14HPGD
SCHEMBL2201356 0.81 MAPK14 (0.57) MAPK13MAPK12MAPK11MAPK14HPGD
SCHEMBL2197033 0.81 MAPK14 (0.62) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL2197758 0.81 KDM4E (0.67) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2201335 0.78 MAPK14 (0.57) MAPK13MAPK12MAPK11MAPK14
SCHEMBL2195634 0.78 MAPK14 (0.54) MAPK13MAPK12MAPK11MAPK14
SCHEMBL27655267 0.77 MAPK14 (0.48) MAPK13MAPK12MAPK11MAPK14CYP3A4
SCHEMBL2202867 0.77 MAPK14 (0.56) MAPK13MAPK12MAPK11MAPK14HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006528597-A 2006-12-21 JP claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP claimed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO claimed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.